Augustinerinnen Krankenhaeuser gGmbH

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Bronchiectasis3 trials
• Idiopathic pulmonary fibrosis3 trials
• COPD1 trial
• Cystic fibrosis1 trial
• Heart failure1 trial
• Obesity1 trial

Phase

• Phase 25 trials
• Phase 33 trials

Status

• Not yet recruiting3 trials
• Recruiting3 trials
• Active, not recruiting2 trials

Lead sponsor

• Bristol-Myers Squibb Services Unlimited Company2 trials
• Chiesi Farmaceutici S.p.A.1 trial
• Expedition Therapeutics Inc.1 trial
• GlaxoSmithKline1 trial
• Novo Nordisk A/S1 trial
• and 2 more

Running trials

• Not yet recruiting

  A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD

  2026-525216-34-00· Phase 2· Expedition Therapeutics Inc.· Source

• Recruiting

  A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

  NCT07720375· Phase 2· UCB Biopharma SRL· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

  NCT07201051· Phase 2· GlaxoSmithKline· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis

  2023-503699-25-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

  2023-503697-21-01· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Recruiting

  Inhalation therapy in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept - randomized controlled trial

  2023-509277-22-00· Phase 2· Philipps-Universitaet Marburg· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bronchiectasis3 recruiting
• COPD1 recruiting
• Cystic fibrosis1 recruiting
• Heart failure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Obesity1 recruiting